Advertisement

Topics

ESMO 2017: Licensing and reimbursement discrepancies impact patient access to cancer treatment

22:06 EDT 9 Sep 2017 | ecancermedicalscience

Discrepancies between licensing and reimbursement decisions have an impact on patient access to cancer treatment, according to research presented at the ESMO 2017 Congress in Madrid. Conducted on behalf of Bristol-Myers Squibb, the study evaluated...

Original Article: ESMO 2017: Licensing and reimbursement discrepancies impact patient access to cancer treatment

NEXT ARTICLE

More From BioPortfolio on "ESMO 2017: Licensing and reimbursement discrepancies impact patient access to cancer treatment"

Quick Search
Advertisement
 

Relevant Topic

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...